BioVie Inc
BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing drug candidates for neurological and neurodegenerative disorders as well as advanced liver disease. Its pipeline centers on bezisterim (NE3107), an orally administered small molecule being studied for inflammatory and insulin-resistance pathways implicated in Alzheimer’s disease, Parkinson’s disease, and Long COVID, and BIV201, a continuous-infusion terlipressin program for liver disease. The company does not currently generate revenue and remains dependent on clinical progress and external financing to fund development. BioVie is a very small organization with a lean internal team and heavy reliance on outside scientific, clinical, and regulatory partners.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueDevelopment of bezisterim for Alzheimer’s disease, Parkinson’s disease, and related inflammatory neurodegenerative indications.
Development of BIV201, a continuous-infusion terlipressin program aimed at advanced liver disease.
Customers
BioVie does not sell commercial products today; its direct counterparties are clinical trial participants, investigators, contract research organizations, laboratories, and other development vendors that enable its programs. If approved, its future customers would likely include physicians, hospitals, and specialty treatment centers prescribing therapies for Alzheimer’s disease, Parkinson’s disease, Long COVID-related inflammation, and advanced liver disease. The company’s end-market is therefore the healthcare system rather than a traditional recurring customer base, with demand driven by unmet medical need and regulatory approval. In the near term, the company’s economic survival depends more on capital providers than on product buyers because it has no revenue and no commercial launch yet.
CROs, trial sites, principal investigators, and labs that execute studies and support regulatory submissions.
Physicians and specialty clinics that could prescribe bezisterim or BIV201 if approved.
Patients with Alzheimer’s disease, Parkinson’s disease, or Long COVID-related inflammatory conditions who represent the eventual treatment population.
Patients who may benefit from BIV201 in advanced liver disease settings if development succeeds.
Equity investors and other capital providers that fund operations before any product revenue exists.
Strategy
BioVie’s strategy is to advance a small number of high-conviction clinical assets rather than build a broad commercial portfolio. The company is prioritizing development of bezisterim and BIV201 through clinical trials, regulatory work, and intellectual property protection in order to create approvable product candidates. Because it has no revenue, capital formation is a core strategic activity and the company explicitly expects to fund operations through equity sales, loans, or strategic transactions. The business model therefore depends on converting clinical data into regulatory value while preserving enough liquidity to continue development.
Clinical data is the main value-creation engine for a company with no revenue and no approved products.
The company has substantial operating cash burn and explicitly states that continued operations depend on external capital.
Patent protection and FDA approval are essential to create defensible commercial value from the pipeline.
Geography
BioVie is headquartered in the United States and its disclosed commercial and scientific focus is primarily U.S.-based. The company also references competition and scientific activity in Europe and elsewhere, indicating that its therapeutic targets are global in scope even though development is still early. Because it has no revenue and no commercial manufacturing footprint disclosed, geography currently matters more for where trials, regulatory interactions, and future market opportunities may occur than for sales concentration. The company’s exposure is therefore tied to U.S. FDA approval pathways and the ability to access international clinical and capital markets as programs advance.
Risks
BioVie faces the classic risks of a clinical-stage biotech company: failure in clinical development, regulatory setbacks, and dependence on third parties to run trials. The company explicitly states that it relies on CROs, clinical sites, investigators, laboratories, manufacturers, and suppliers, so execution risk is partly outside management’s control and can delay or derail approval. It also has no revenue and has disclosed substantial doubt about its ability to continue as a going concern, making financing risk a central business risk rather than a secondary concern. More broadly, the company competes against larger biopharmaceutical firms with greater capital, broader IP portfolios, and more resources to sustain long development cycles and patent disputes.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s value depends on proving safety and efficacy in trials for bezisterim and BIV201.
Exposure: Pipeline programs
- Going-concern / financing riskImpact: CriticalLikelihood: High
The company has no revenue and states that future operations depend on additional financing.
Exposure: Corporate liquidity
- Dependence on third-party trial executionImpact: HighLikelihood: Medium
CROs, sites, investigators, and labs control key parts of the development process and can miss deadlines or fail compliance requirements.
Exposure: Clinical operations
- Competition from larger biopharma firmsImpact: HighLikelihood: Medium
Competitors have greater resources, broader IP portfolios, and more ability to fund long development timelines.
Exposure: Market positioning
- Intellectual property uncertaintyImpact: MediumLikelihood: Medium
Patent applications may not issue or be enforceable, reducing protection for future products.
Exposure: Bezisterim and BIV201
Accounting
Judgemental itemsClinical trial and consultant costs are recognized as incurred and estimates can shift with trial timing and vendor invoices.
Impact: Affects operating loss and quarterly comparability
Changes in fair value of embedded or standalone derivatives can materially affect other income and expense without cash impact.
Impact: Creates earnings volatility
Equity awards are used to compensate employees and consultants, requiring fair value estimates and amortization over service periods.
Impact: Raises reported operating expenses
The company’s ability to continue depends on future capital raises, so disclosure judgments are central to financial analysis.
Impact: Frames solvency and financing risk
Similar listed companies
Publicly listed companies with a comparable business focus.
BioAge Labs, Inc.
BIOA · Pharmaceutical Preparations
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
CervoMed Inc.
CRVO · Pharmaceutical Preparations
Biohaven Ltd.
BHVN · Pharmaceutical Preparations
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
Last updated: 24/09/2026